Therapeutic Plasma Exchange (TPE) for Covid-19 Cytokine Release Storm (CRS)
Keywords
Abstract
Description
PROTOCOL SUMMARY:
Long title: Proposed use of TPE (therapeutic plasma exchange), to Limit Coronavirus Associated Complications: An Open label, Phase 2 Study
Clinical Phase: Two arms, Phase 2 Open Label
Conducted by: Department of Pulmonology and Critical Care; Pak Emirates Military Hospital.
Sample Size: 280
Study Population: Hospitalized COVID-19 patients aged ≥18 years to 80 years of with Moderate- severe-critical disease and evidence of Cytokine release storm (CRS)
Study Duration: 1st April, 2020 to 30th June 2020
Study Design: This open label phase 2 trial will assess the efficacy and safety of following treatment options
1. Standard treatment including steroids
2. Therapeutic plasma exchange in addition to standard treatment
Operational Definitions
1. Moderate disease:
COVID-19 positive case with lung infiltrates < 50% of total lung fields on Chest X-ray / peripheral ground glass opacities (GGOs) on High Resolution Computerized Tomography (HRCT)chest but no evidence of hypoxemia.
2. Severe disease:
COVID-19 pneumonia with evidence of hypoxemia (RR > 30/minute or PaO2 on ABGs < 80mmHg or PaO2/FiO2 (PF ratio) < 300 or lung infiltrates > 50% of the lung field).
3. Critical illness:
COVID-19 pneumonia with evidence of either respiratory failure (PaO2 < 60mmHg) or multiorgan dysfunction syndrome (MODS) measured by Sequential Organ Failure assessment (SOFA score) > 10 or septic shock (Systolic BP less than 90 or less than 40mm Hg of baseline in hypertensive or Urine output < 0.5 ml/kg/hour).Age, sex, comorbidities, date of symptoms, source of infection, type of admission SOFA score, Clinical status, vital signs including temperature, respiratory rate, oxygen saturation, oxygen requirement, Complete Blood counts (CBC) with neutrophil counts, lymphocytes count, C-reactive Proteins (CRP), chest imaging (CT or X-ray), location and status in hospital
4. Cytokine release storm (CRS):
Diagnostic criteria of Cytokine release syndrome (CRS) CRS is defined as fever of equal to or more than 100 F persisting > 48 hours in absence of documented bacterial infection and ANY of the following in the presence of moderate, severe or critical disease
1. Ferritin >1000 mcg/L and rising in last 24 hours
2. Ferritin >2000 mcg/L in patient requiring high flow oxygen or ventilation
3. Lymphopenia < 800 cells/ul or lymphocyte percentage <20% and two of the following
1. Ferritin >700 mcg/mL and rising in the last 24 hours
2. LDH > 300 IU (reference 140-250 IU/L) and rising in the last 24 hours
3. D-Dimer >1000ng/mL (or >1mcg/ml) and rising in the last 24 hours
4. CRP >70 mg/L (or >10 hsCRP) and rising in the last 24 hours, in absence of bacterial infection
5. If any 3 of above presents on admission no need to document rise
5. Standard treatment:
As per Institutional COVID-19 Management Guidelines all patients of moderate, severe and critical COVID-19 received standard protocol of aspirin, anticoagulation, ulcer prophylaxis, awake Proning (if PaO2 < 80mmHg) and corticosteroids. All patients of CRS received Methylprednisolone 1 mg/kg irrespective of disease severity.
6. Therapeutic Plasma exchange (TPE)
Therapeutic plasma exchange: 1-1.5 plasma exchange daily (1-5 sessions) with replacement fluid Fresh frozen Plasma (FFP) (whole volume) to 70 willing patients of moderate, severe and critical disease with evidence of CRS after explaining the investigational role of this therapy. TPE will be given in addition to standard treatment to 70 patients randomly. TPE related complications to be documented
7. Recovery Recovery to be defined by de-escalation of patients condition from severe to moderate, or from moderate to mild, plus at least 2 of the following; serum Ferritin < 1000 ug/ml (and decreasing trend on two consecutive days), serum LDH normalization, C-reactive protein > 50% fold reduction (and decreasing trend in on two consecutive days),), ALC > 1000 and PT/APTT normalization.
Dates
Last Verified: | 06/30/2020 |
First Submitted: | 07/20/2020 |
Estimated Enrollment Submitted: | 07/21/2020 |
First Posted: | 07/23/2020 |
Last Update Submitted: | 07/21/2020 |
Last Update Posted: | 07/23/2020 |
Actual Study Start Date: | 03/31/2020 |
Estimated Primary Completion Date: | 06/29/2020 |
Estimated Study Completion Date: | 06/29/2020 |
Condition or disease
Intervention/treatment
Procedure: TPE Arm
Phase
Arm Groups
Arm | Intervention/treatment |
---|---|
Experimental: TPE Arm In addition to standard care TPE was performed once daily using COBE Spectra Apheresis machine version 7 (Manufacturer TERUMO BCT, Lakewood, CO, USA INC) having continuous flow centrifugation. Venous access was achieved using an ultrasound guided double lumen catheter (Arrow - 12 FR) via femoral vein. Patient's total blood volume was calculated as per Nadler's formula. Anticoagulant acid dextrose ratio was 1:10 and flow rate 30-40 ml/minutes (Adjusted as per hemodynamic status). Patients' blood pressure, pulse, oxygen saturation was monitored throughout procedure. Duration of procedure varied from 2-4 hours and 1-1.5 times total plasma volume was removed during each procedure. Replacement fluid was fresh frozen plasma (FFP) and normal saline in 2:1 respectively. All procedures were performed in intensive care or high dependency unit by Apheresis Department of PEMH. TPE was continued till recovery | Procedure: TPE Arm a. 1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily |
No Intervention: NON TPE arm Only supportive treatment offered including Vit C, Zinc, Vit D, famotidine, Enoxaparin and Methylprednisolone |
Eligibility Criteria
Ages Eligible for Study | 18 Years To 18 Years |
Sexes Eligible for Study | All |
Accepts Healthy Volunteers | Yes |
Criteria | Inclusion Criteria: - COVID-19 diagnosed by Polymerase Chain Reaction (PCR) positivity for SARS-CoV2 - CRS at presentation or developing during hospitalization - 10-80 years age and both genders - hospital admission - At least 1 completed session of plasma-exchange in patients included in TPE arm - No other novel therapy administered. Exclusion criteria were: - Death within 48 hours of admission - severe septic shock at time of admission - Congestive cardiac failure (EF<20%) (4) - Those receiving immunotherapy, Anti-thymocyte globulin or hematopoietic stem cell transplant in recent past - Patients of hematological or solid organ malignancies - patients receiving other investigational drugs including Tocilizumab, Convalescent plasma, Remdesivir, or Mesenchymal stem cells. |
Outcome
Primary Outcome Measures
1. Survival [28 days]
Secondary Outcome Measures
1. Duration of Hospitalization [28 days]
2. Timing of PCR negativity [28 days]
3. Time to CRS resolution [28 days]
4. Complications [28 days]